CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS

Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
Masaru HasumiNobuaki Shimizu

Abstract

(Objective) We retrospectively evaluated the clinical efficacy and safety of abiraterone acetate (AA) in patients with castration-resistant prostate cancer (CRPC). (Methods) We analyzed the clinical records of 50 patients who had received AA in Gunma Cancer Center between October 2014 and June 2017. We assessed the response of prostate-specific antigen (PSA) to AA, and analyzed the association between overall survival and various parameters, including the types of primary hormonal therapy, PSA level, Gleason score, time to CRPC, prior treatment with enzalutamide (Enz) and docetaxel, and sites of metastases. (Results) The median patient age was 74.5 years and median PSA level at baseline was 15.9 ng/ml; 39 (78%) patients had Gleason score ≥8. Eleven (45.8%) of the 24 docetaxel-naïve patients achieved >50% reduction in PSA level from baseline as opposed to one (4.5%) of the 22 patients previously treated with docetaxel.Eleven (55%) of the 20 Enz-naïve patients achieved >50% reduction in PSA level from baseline compared to one (3.8%) of the 26 patients previously treated with Enz. The overall survival of the group with time to CRPC >12 months was significantly longer than that of the group with time to CRPC <12 months (p=0.035). I...Continue Reading

References

Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter S Nelson
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Jul 8, 2014·Clinical Genitourinary Cancer·Salvatore L BurgioUgo De Giorgi
Sep 4, 2014·The New England Journal of Medicine·Emmanuel S AntonarakisJun Luo
Jun 9, 2015·Critical Reviews in Oncology/hematology·Giandomenico RovielloEdoardo Francini
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola
Apr 30, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Naoki TeradaEmmanuel S Antonarakis
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Mar 1, 2018·World Journal of Urology·Sebastian FreesAlan So

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.